Trump's tariffs threaten to take the fizz out of Champagne's crucial U.S. market
VERZENAY — Champagne producers in northeastern France need to find new markets after U.S. President Donald Trump threatened 30 per cent tariffs on EU exports, the chairman of a French industry group said, suggesting Brazil, Southeast Asia and South Africa as options.
The U.S. is the biggest market for champagne with 10 per cent of champagne exports by volume and 15 per cent by value and producers say the tariffs will push up prices for consumers and threaten jobs all along the supply chain, including in the United States.
'The repercussions for all family champagne exports will be severe because it will mean lost income from bottle sales, which will also affect the grape harvest quotas we will be allowed to collect,' said Stephane Vignon, whose family has been producing Champagne in Verzenay since 1946.
With 70 per cent of champagne sales currently concentrated in just five countries, tariffs should push producers to seek new markets, said Maxime Toubart, chairman of industry group Comite Champagne (Champagne Committee).
He said France's cognac industry, which is mainly reliant on exports to China and the U.S. where it could also face duties, provides a cautionary tale for champagne producers on the need to diversify. But replacing U.S. sales is not easy, he said.
'We can't just say we'll sell three million fewer bottles in the U.S. and put them in Japan instead. So actually, there is no alternative today to this fall in volume,' he said.
Total champagne exports fell more than 10 per cent last year but rose slightly in the first four months of 2025 ahead of a 10% tariff in April, farm office France Agri Mer said.
'If tomorrow the 30% tariff is implemented, I think it will definitely impact the relationship,' said Hugo Drappier of the Drappier Champagne house. 'We've always managed to build a relationship of trust with our clients through the quality of our wines ... Let's hope that relationship isn't broken.'
(Writing and additional reporting by Sybille de La Hamaide and Michaela Cabrera. Editing by Gabriel Stargardter and Sharon Singleton)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 minutes ago
- Globe and Mail
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion by the end of the decade. Oncology, at present, comprises around 27% of J&J's total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, contributed significantly to growth as they witnessed strong launches. Though the $50 billion target was well above consensus, J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. Meanwhile, J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. If these pipeline drugs are eventually approved, they can also boost JNJ's oncology sales. In the five years from 2019 to 2024, J&J's oncology sales have doubled from $10.7 billion in 2019 to $20.8 billion in 2024. To achieve the $50 billion target in the next 5-6 years, the company needs to more than double its sales from 2024 levels. Though quite optimistic, the target is not unachievable. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, AstraZeneca AZN, Merck MRK and Bristol-Myers. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena and the Braftovi-Mektovi combination. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. For AstraZeneca, oncology sales now comprise around 41% of total revenues. AstraZeneca's strong oncology sales growth is being driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI1inhibitor, Opdivo, which accounts for around 20% of its total revenues. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 14.6% in the year-to-date period compared with an increase of 1.5% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.97 forward earnings, slightly lower than 15.04 for the industry. The stock is also trading below its five-year mean of 15.70. The Zacks Consensus Estimate for 2025 earnings has risen from $10.60 per share to $10.66 over the past 30 days, while that for 2026 has risen from $10.98 to $11.13 over the same timeframe. J&J has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
National Post
6 minutes ago
- National Post
EU to triple travel permit fee to 20 euros
Brussels (Belgium) (AFP) — The digital travel permit for foreigners to enter the European Union should cost 20 euros ($23), almost triple the original planned fee, under a proposal published Friday. Article content The adjustment to the yet-to-be implemented ETIAS scheme for visa-exempt nationals comes as the European Commission seeks to boost its financial resources to fund an array of priorities from defence to agriculture. Article content Article content The change reflects inflation and additional operational costs, the commission said. Article content Article content 'It will also bring the cost for a travel authorisation to the EU in line with similar travel authorisation programmes,' the EU's top executive body said. Article content Adopted in 2018, the European Travel Information and Authorisation System (ETIAS) regulation originally envisaged a fee of seven euros. Article content Britain's equivalent, known as ETA, comes with a 16 pound fee ($21), while the United States' ESTA permit costs $21. Article content Obtainable online, the European Union's ETIAS permit will be required for the bloc's 27 countries with the exception of Ireland, as well as for Norway, Iceland, Switzerland and Liechtenstein. Article content The permit, valid for three years, will be required for non-EU nationals from countries whose citizens do not need a visa for short stays in Europe, such as Canada, Britain and the United States. Article content Those aged under 18 or over 70 years will be exempt from the fee. Article content Brussels said the scheme was created to identify security, irregular migration and other risks as well as to facilitate border crossing for regular travellers. Article content But its implementation, which was supposed to go hand-in-hand with a new automated border check system, has suffered from delays. Article content The European Parliament and member states have two months to review the new 20-euro fee, which will enter into effect as soon as ETIAS becomes operational — now expected for the last quarter of 2026. Article content This week the commission proposed a boosted two-trillion-euro long-term budget for 2028-2034, which has already upset some of the EU countries that will have to chip in most of the money. Article content As part of the blueprint, which is subject to negotiation, Brussels said it will seek to raise about 58 billion euros a year collecting money directly through measures like its carbon border tax and a levy on electronic waste.
CTV News
2 hours ago
- CTV News
EU to triple travel permit fee to 20 euros
Travellers wait in line at the Ottawa International Airport in Ottawa on Thursday, July 3, 2025. THE CANADIAN PRESS/Sean Kilpatrick The digital travel permit for foreigners to enter the European Union should cost 20 euros, almost triple the original planned fee, under a proposal published Friday. The adjustment to the yet-to-be implemented ETIAS scheme for visa-exempt nationals comes as the European Commission seeks to boost its financial resources to fund an array of priorities from defence to agriculture. The change reflects inflation and additional operational costs, the commission said. 'It will also bring the cost for a travel authorisation to the EU in line with similar travel authorisation programmes,' the EU's top executive body said. Adopted in 2018, the European Travel Information and Authorisation System (ETIAS) regulation originally envisaged a fee of seven euros. Britain's equivalent, known as ETA, comes with a 16 pound fee, while the United States' ESTA permit costs US$21. Obtainable online, the European Union's ETIAS permit will be required for the bloc's 27 countries with the exception of Ireland, as well as for Norway, Iceland, Switzerland and Liechtenstein. The permit, valid for three years, will be required for non-EU nationals from countries whose citizens do not need a visa for short stays in Europe, such as Canada, Britain and the United States. Those aged under 18 or over 70 years will be exempt from the fee. Brussels said the scheme was created to identify security, irregular migration and other risks as well as to facilitate border crossing for regular travellers. But its implementation, which was supposed to go hand-in-hand with a new automated border check system, has suffered from delays. The European Parliament and member states have two months to review the new 20-euro fee, which will enter into effect as soon as ETIAS becomes operational -- now expected for the last quarter of 2026. This week the commission proposed a boosted two-trillion-euro long-term budget for 2028-2034, which has already upset some of the EU countries that will have to chip in most of the money. As part of the blueprint, which is subject to negotiation, Brussels said it will seek to raise about 58 billion euros a year collecting money directly through measures like its carbon border tax and a levy on electronic waste.
